Administration Guidance

Spinosad Topical Suspension 0.9% can eradicate head lice infestations with a single, 10-minute application—no nit combing required. However, if live lice are seen seven days after the first treatment, a second treatment should be applied.

English

Watch a clinician demonstrate the proper application technique.

Properly Applying Spinosad Topical Suspension 0.9%

  • Use as much product as needed to completely cover the scalp first, and then apply outwards towards the ends of the hair.
  • For very thick, medium-length or long hair, an entire bottle (120 mL) of Spinosad Topical Suspension 0.9% may be needed to cover the scalp and hair. For shorter, thinner hair, less Spinosad Topical Suspension 0.9% may be needed.
  • If live lice are seen seven days after the first treatment, re-apply Spinosad Topical Suspension 0.9%.
Español

Un proceso tan fácil como 1-2-3 para aplicar la suspención tópica Spinosad correctamente.

Pasos Importantes: Pon fin al ciclo del piojo

  • Cubra completamente el cuero cabelludo primero y luego aplique hacia afuera hacia las puntas del cabello. Es importante utilizar suficiente SPINOSAD suspensión tópica 0.9% para cubrir todo el cuero cabelludo y todo el cabello.
  • Para cabellos muy gruesos y de longitud media o cabellos largos, se puede necesitar una botella entera (120 ml) de SPINOSAD suspensión tópica 0.9% para cubrir el cuero cabelludo y el cabello. Es posible que se necesite menos SPINOSAD suspensión tópica 0.9% para cabellos más cortos y finos.
  • Una semana (7 días) después de su primer tratamiento, si se ven piojos vivos, repita el tratamiento otra vez.

Important: For topical use only on scalp and scalp hair. Do not get Spinosad Topical Suspension 0.9% in eyes, mouth, or vagina.

Adjunctive measures

Spinosad Topical Suspension 0.9% should be used in the context of an overall lice management program:

• Wash (in hot water) or dry clean all recently worn clothing, hats, used bedding and towels
• Wash personal care items such as combs, brushes, and hair clips in hot water
• A fine-toothed comb or special nit comb may be used to remove dead lice and nits

Indication
Spinosad Topical Suspension 0.9% is a pediculicide indicated for the topical treatment of head lice infestations in patients six (6) months of age and older.

Adjunctive Measures
Spinosad Topical Suspension 0.9% should be used in the context of an overall lice management program:
• Wash (in hot water) or dry clean all recently worn clothing, hats, used bedding and towels
• Wash personal care items such as combs, brushes, and hair clips in hot water
• A fine-toothed comb or special nit comb may be used to remove dead lice and nits.

Important Safety Information
Spinosad Topical Suspension 0.9% contains benzyl alcohol and is not recommended for use in neonates and infants below the age of 6 months. Systemic exposure to benzyl alcohol has been associated with serious adverse reactions and death in neonates and low birth-weight infants when administered intravenously. Most common adverse events were: application site redness (3%), eye redness (2%) and application site irritation (1%).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Reference(s)
  1. Spinosad Topical Suspension 0.9% Prescribing Information

SPN-RRW11-002

Important Safety Information

Indication
Spinosad Topical Suspension 0.9% is a pediculicide indicated for the topical treatment of head lice infestations in patients six (6) months of age and older.

Adjunctive Measures
Spinosad Topical Suspension 0.9% should be used in the context of an overall lice management program:
• Wash (in hot water) or dry clean all recently worn clothing, hats, used bedding and towels
• Wash personal care items such as combs, brushes, and hair clips in hot water
• A fine-toothed comb or special nit comb may be used to remove dead lice and nits.

Important Safety Information
Spinosad Topical Suspension 0.9% contains benzyl alcohol and is not recommended for use in neonates and infants below the age of 6 months. Systemic exposure to benzyl alcohol has been associated with serious adverse reactions and death in neonates and low birth-weight infants when administered intravenously. Most common adverse events were: application site redness (3%), eye redness (2%) and application site irritation (1%).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.